RuiXun Biotech Secures Tens of Millions in Series C1 Financing, Appoints Hygeia Capital as Exclusive Financial Advisor

VCBeat has learned that RainSure Scientific, an industry leader specializing in molecular diagnostics and life sciences with a proprietary microfluidics technology platform, recently completed a tens-of-millions-yuan Series C1 financing round. The round was led by Qiandao Fund, with Haoyue Capital serving as the exclusive financial advisor.

RainSure Scientific was established in 2017 and is headquartered in the Suzhou Industrial Park, with a wholly-owned subsidiary, PreciGenome LLC, based in Silicon Valley, USA, focusing on life science product lines. Leveraging its independently developed core microfluidics platform, the company has launched a series of digital PCR systems and microfluidics-related devices, striving to become an industry leader in molecular diagnostics and life sciences. The founding team members are graduates of Ivy League and other top-tier universities in the United States and have previously worked at renowned biotechnology companies such as Bio-Rad, Sysmex, and Complete Genomics. They have participated in or led the development of multiple well-known industry products, boasting a senior R&D team with rare comprehensive expertise covering instruments, reagents, and chips.

Meanwhile, the company possesses a strong inherent capability for global expansion, with its globalization strategy yielding significant results. Overseas revenue now accounts for 40% of the total, and its product strength has been widely recognized by top-tier customers both domestically and internationally. Its life science products have been adopted by prestigious institutions such as Yale University and Harvard Medical School, further broadening the company’s development prospects. To date, over 40 publications have featured RainSure SCIENTIFIC’s digital PCR products and microfluidic products from its U.S. subsidiary, PreciGenome. These include high-impact journals such as Nature Chemical Biology, Lab on a Chip, and Analytical Chemistry, with a cumulative impact factor exceeding 250 and more than 380 citations.

Researchers at the University of Salerno used RainSure SCIENTIFIC’s LNP equipment, Nanogenerator Flex

In the molecular diagnostics product line, the company possesses the only digital PCR system in China approved with NMPA, CE, and FDA-EUA certifications. It also assisted in establishing China’s first local standard for technical specifications of digital PCR testing for the novel coronavirus. Through innovation in core technological pathways and process optimization, its digital PCR system features advantages such as high automation and an integrated design, targeting three major clinical scenarios: infectious diseases, hematologic malignancies, and liquid biopsy for solid tumors. The company’s products have been installed and clinically validated at several top-tier tertiary hospitals, including Ruijin Hospital, Huashan Hospital, Dongfang Hospital, and Renji Hospital. Continuously striving to create more integrated and user-friendly digital PCR products for clinical and research users, the company is developing a point-of-care testing (POCT) digital PCR system based on microfluidic cartridges. As there are currently no similar POCT-style products globally, this system is poised to become the first innovative product of its kind in the clinical and research markets.

Installation at Tertiary Grade A Hospitals

In the life sciences product line, RainSure SCIENTIFIC is among the first domestic leading manufacturers to deploy microfluidic LNP technology. The explosive growth in mRNA vaccine and drug research has generated substantial demand for microfluidic LNP delivery systems, which are currently in short supply globally. The company has already begun supplying top-tier customers both domestically and internationally, offering a comprehensive portfolio that covers the full lifecycle from research-grade and pilot-scale to GMP-compliant solutions. Notably, it has become the first Chinese-made LNP product to be cited in literature by overseas clients, with related findings published in the International Journal of Pharmaceutics.

Overseas User Product Promotion Conference

As the third-generation PCR technology, digital PCR (dPCR) offers core advantages such as absolute quantification, high sensitivity, and accuracy, holding significant clinical potential in areas like infectious diseases, hematologic malignancies, and liquid biopsy for solid tumors. To date, nearly all major life science and diagnostics giants have either launched their own dPCR products or invested in and acquired dPCR technologies. Domestic IVD listed companies, such as Maccura Biotechnology and Anbiping, have also recently made strategic moves to identify new growth drivers. RainSure SCIENTIFIC, a leading player in the global genetic testing industry with robust R&D capabilities for continuous innovation, is poised to make a substantial contribution to the healthy and rapid development of the sector and to enhancing the international influence of Chinese brands.

Ms. Wang Yaqi, Chairwoman of RainSure SCIENTIFICRainSure SCIENTIFIC expressed its delight in partnering with QianDao Fund in this funding round and extended its sincere gratitude to QianDao Fund and the co-investors for their strong support. The proceeds from this round will be allocated to further R&D of new products, domestic and international clinical registration of products under development, optimization of existing production lines and capacity expansion, as well as the expansion of top-tier sales, technical support, and after-sales teams both domestically and internationally to strengthen product marketing and user education. Committed to forging ahead, achieving long-term success, and innovating in intelligent manufacturing, RainSure SCIENTIFIC will continue to serve a broader global user base with leading products, creating greater value for users, investors, and the industry.

Ms. Song Weinan, Senior Investment Director at QianDao FundQianDao Fund has been closely monitoring the development of the molecular diagnostics industry chain and the application of microfluidics technology. In the field of molecular diagnostics, digital PCR is an area where domestic substitution is urgently needed to address critical technological bottlenecks. As an industry leader deeply rooted in molecular diagnostics and life sciences, RainSure SCIENTIFIC has developed a leading third-generation digital PCR system and a comprehensive end-to-end solution based on its proprietary advanced microfluidics technology platform. Its molecular diagnostics product line covers multi-disease and multi-scenario testing, achieving significant technical advantages in speed and sensitivity.RainSure SCIENTIFIC’s life sciences product line, built upon the company’s microfluidics technology, provides microfluidic equipment to mRNA enterprises, single-cell sequencing companies, and organ-on-a-chip providers. The company has also successfully expanded its products overseas. Currently, RainSure SCIENTIFIC’s independently developed microfluidic research equipment serves numerous clients in China, Europe, and the United States, positioning the company among the top-tier suppliers of microfluidic research equipment.With the explosive growth of the mRNA vaccine and nucleic acid drug markets, the global market potential for microfluidic LNP (lipid nanoparticle) technology is immense. As the core delivery system for RNA therapies, and given the diversification of mid- and downstream application scenarios, microfluidic LNP technology will become one of the key growth drivers for RainSure SCIENTIFIC’s future core business.We remain firmly optimistic about RainSure SCIENTIFIC’s dual-drive strategy in molecular diagnostics and life sciences. By breaking foreign technological monopolies and pursuing a global commercial layout, RainSure SCIENTIFIC is poised to grow into a globally leading life sciences company headquartered in China.

Mr. Li Yishi, Senior Partner at Haoyue CapitalHaoyue Capital is honored to have served as the exclusive financial advisor for RainSure SCIENTIFIC in this round of financing, assisting the company in successfully closing the deal. With its core microfluidics technology platform, RainSure SCIENTIFIC has developed a product pipeline that includes digital PCR systems and LNP production equipment, establishing itself as a leading enterprise in these fields. The company not only possesses strong independent R&D capabilities that effectively address the genuine needs of clinical and research markets, but also provides a successful reference model for Chinese hard-tech brands expanding into global markets. The founding team’s sustained innovation capability and efficient execution have been fully recognized by both new and existing shareholders, driving the company to continuously break through barriers and reach new heights. We remain optimistic about the company’s future prospects and look forward to RainSure SCIENTIFIC’s continued success!

RainSure SCIENTIFIC is an innovative biotechnology company dedicated to technological innovation in the life sciences sector. Adhering to its mission of “Innovation, Intelligent Manufacturing, and Empowering Health,” RainSure leverages cutting-edge microfluidics technology, advanced optical platforms, and leading software systems to build a world-class molecular diagnostics platform. The founding team members of RainSure all hold PhDs from Ivy League institutions and other top-tier international universities, boasting solid academic backgrounds and extensive industry experience. The core team has previously worked at prestigious, established biotechnology companies, where they participated in and led the development of multiple well-known industry products. Since its establishment, RainSure has secured nearly RMB 100 million in investments from prominent domestic venture capital firms, including ZhenFund, Volcanic Stone Capital, Mingshi Capital, and Yuansheng Venture Capital. Committed to innovation as its core competitive advantage, RainSure has successfully launched multiple products, including the DropDx-2044 Digital PCR System and NanoGenerator^™Nanoparticle synthesis systems, over 100 RUO assay kits, and more. RainSure SCIENTIFIC implements high-standard quality control at every stage of product development, committed to providing high-quality, high-performance products to each customer, and has received widespread acclaim from numerous hospitals, pharmaceutical companies, and research users in China.

QianDao Fund was established in 2011. Adhering to the philosophy of “empowering finance with technology, serving industries through financial services, and contributing to the nation through industrial development,” the firm specializes in asset management and investment activities, including equity investment and industrial investment. QianDao Fund has cumulatively initiated, established, and registered more than 50 private equity funds. In the biopharmaceutical sector, QianDao Fund strategically focuses on high-quality segments such as innovative drugs (including biopharmaceuticals), in vitro diagnostics (IVD), innovative medical devices, healthcare services, and health tech. By collaborating with biopharmaceutical industry institutions, the fund jointly explores diversified layouts and innovative development models for the biopharmaceutical industry.

Founded in January 2014, Hylink Capital is a leading industry-focused investment bank specializing in the healthcare sector in China. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Committed to empowering growth through capital and research-driven insights, Hylink Capital helps outstanding Chinese healthcare enterprises successfully access the capital markets, thereby creating added value for its clients. The partnership team comprises senior investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Hylink Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, Hylink Capital completed more than 50 complex transactions involving private financing, mergers and acquisitions, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, securing a leading position across various healthcare sub-sectors.